Virax Biolabs Group Ltd
VRAXHealthcare·Biotechnology·United Kingdom·Nano·NASD·Nov 11 • 3:58 PM ET
0.6271-0.0170 (-2.64%)
2026-11-12 06:32 CET
Market cap
0.84 USD m
Revenue, TTM
0.01 USD m
Net income, TTM
-5.02 USD m
Free cash flow, TTM
-4.87 USD m
EPS diluted, TTM
-16.91
P/E
-
Price
VRAX against its 20, 50 and 200-day averages2050200
97.1% under the 52-week high of 21.75 on 3 Dec 2025. 52-week low 0.50 on 10 Nov 2026. Last 15 sessions, 212.1% high to low
Volume 0.36× normal · the line is the 50-bar volume average
Profile
VRAX52-week range, 1% of the way up
0.5021.75
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.
| Employees | 26 |
|---|---|
| IPO | Jul 21, 2022 |
| Beta | 1.57 |
| ATR, 14d | 0.22 |
| Rel volume | 0.36 |
| Short float | 0.50% |
| Insider own | 0.37% |
| Inst own | 1.98% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 0.85M |
| Enterprise Value | -5.42M |
| Income | -5.02M |
| Sales | 0.01M |
| Book/sh | 13.08 |
| Cash/sh | 4.77 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 26 |
| IPO | Jul 21, 2022 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | 84.70 |
| P/B | 0.05 |
| P/C | 0.13 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | -542.30 |
| Quick Ratio | 9.97 |
| Current Ratio | 9.97 |
| Debt/Eq | 0.05 |
| LT Debt/Eq | 0.04 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -16.91 |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | 53.83% 2.45% |
| Sales past 3/5Y | 13.21% -36.86% |
| EPS Y/Y TTM | 58.99% |
| Sales Y/Y TTM | 96.22% |
| EPS Q/Q | 75.64% |
| Sales Q/Q | 684.83% |
| Earnings | - |
| EPS/Sales Surpr. | - - |
Ownership
| Insider Own | 0.37% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 1.98% |
| Inst Trans | 4.66% |
| ROA | -68.11% |
| ROE | -75.70% |
| ROIC | -63.74% |
| Gross Margin | -3472.01% |
| Oper. Margin | -51515.17% |
| Profit Margin | -40439.10% |
| SMA20 | -45.61% |
| SMA50 | -66.44% |
| SMA200 | -82.88% |
| Trades | - |
Technical
| Shs Outstand | 1.34M |
|---|---|
| Shs Float | 1.34M |
| Short Float | 0.50% |
| Short Ratio | 0.01 |
| Short Interest | 0.01M |
| 52W High | 21.75 -97.12% |
| 52W Low | 0.50 24.62% |
| Volatility | 35.40% 18.48% |
| ATR (14) | 0.22 |
| RSI (14) | 20.62 |
| Beta | 1.57 |
| Rel Volume | 0.36 |
| Avg Volume | 624.79K |
| Volume | 226,148 |
Performance
| Perf Week | -47.74% |
|---|---|
| Perf Month | -63.92% |
| Perf Quarter | -77.76% |
| Perf Half Y | -82.03% |
| Perf YTD | -92.75% |
| Perf Year | -94.62% |
| Perf 3Y | -99.04% |
| Perf 5Y | - |
| Perf 10Y | - |
| Recom | 1.00 |
| Target Price | 25.00 |
| Prev Close | 0.64 |
| Price | 0.63 |
| Change % | -2.64% |
Analyst ratings
latest 1 of 1| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Mar 31, 2025 | Initiated | HH.C. Wainwright | Buy | $3 | +378.4% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc | 5.68M |
| XGN | Exagen Inc | 121.98M |
| BIAF | BioAffinity Technologies Inc | 4.41M |
| BDSX | Biodesix Inc | 112.22M |
| TRIB | Trinity Biotech Plc ADR | 3.72M |
| ANIX | Anixa Biosciences Inc | 96.65M |
| BJDX | Bluejay Diagnostics Inc | 3.13M |
| ISPC | iSpecimen Inc | 1.79M |
| BMRA | Biomerica Inc | 6.95M |
| CSTL | Castle Biosciences Inc | 1.05B |
News
latest 14 of 190- Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China (PR Newswire) +10.00%
- Why is Cathie Wood's ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD) (FinanceWire) +13.04%
- Virax Biolabs enters immune profiling product supply deal with Fosun (Medical Device Network)
- Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds (PR Newswire) -35.85%
- Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds (PR Newswire) +100.00%
- Virax Biolabs Shares Double After Exclusive Fosun Distribution Agreement (VRAX) (InvestorsHub)
- Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics (PR Newswire)
- Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation (PR Newswire) -14.78%
- Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes (PR Newswire) -18.20%
- BC-Most Active Stocks (Associated Press) +53.09%
- Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders (PR Newswire) -11.06%
- BC-Most Active Stocks (Associated Press) +59.85%
- BC-Most Active Stocks (Associated Press) +7.14%
- BC-Most Active Stocks (Associated Press) +35.32%
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2025S1 | 2025-12-03 | -12.250 | - | - | 0.00 | - | - |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2022FY | -127.5 | - | -128.35 | 0.00 | - |
| 2024FY | -37.000 | -37.000 | -40.621 | 0.03 | 0.03 |
| 2025FY | - | -25.250 | -12.636 | - | 0.04 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2025FY | S | 2025-05-28 | 1 | 0 | 0 | 0.04 | 0.04 | 0.04 |
| 2025FY | S | 2025-03-28 | 1 | 0 | 0 | 0.04 | 0.04 | 0.04 |
| 2025FY | E | 2025-05-28 | 1 | 0 | 0 | -1.01 | -1.01 | -1.01 |
| 2025FY | E | 2025-03-28 | 1 | 0 | 0 | -1.01 | -1.01 | -1.01 |
| 2023FY | S | 2023-12-28 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-27 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-26 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-25 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-24 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-23 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-22 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-21 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-20 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
| 2023FY | S | 2023-12-19 | 1 | 0 | 0 | 1.40 | 1.40 | 1.40 |
Estimate history
| EPS, annual | -15.615 | -14.308 | -37.56 | -128.353 | -83.9 | -40.621 | -12.636 |
|---|---|---|---|---|---|---|---|
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| EPS, quarterly | |||||||
| Period | |||||||
| Sales, annual | 0.1 | 0.124 | 0 | 0.009 | 0.156 | 0.006 | 0.012 |
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Sales, quarterly | |||||||
| Period | |||||||
| Shares, annual | 0.045 | 0.045 | 0.045 | 0.062 | 0.103 | 0.174 | 0.579 |
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Shares, quarterly | |||||||
| Period |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.01 | 0.01 | 0.01 | 0.16 | 0.01 | 0.00 | 0.12 | 0.10 |
| Cost of Goods Sold Incl. D&A | 0.44 | 0.44 | 0.40 | 0.11 | 0.01 | 0.00 | 0.13 | 0.05 |
| Gross Profit | -0.43 | -0.43 | -0.40 | 0.05 | -0.00 | 0.00 | -0.01 | 0.05 |
| Selling, General and Administrative Excl. Other | 5.97 | 5.97 | 5.77 | 6.16 | 5.73 | 1.73 | 0.64 | 0.70 |
| Research and Development | 3.74 | 3.74 | 1.78 | 1.56 | 0.40 | 0.43 | 0.12 | 0.09 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.40 | -6.40 | -6.16 | -6.11 | -5.73 | -1.73 | -0.64 | -0.65 |
| Interest Expense | 0.06 | 0.06 | 0.06 | 0.03 | 0.02 | 0.02 | 0.03 | 0.09 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -5.93 | -5.93 | -6.20 | -6.74 | -5.46 | -1.75 | -0.67 | -0.74 |
| Income Taxes | -0.90 | -0.90 | -0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -5.03 | -5.03 | -6.07 | -6.74 | -5.46 | -1.75 | -0.67 | -0.74 |
| Net Income From Continuing Operations | -5.02 | -5.02 | -6.06 | -6.73 | -5.46 | -1.71 | -0.65 | -0.71 |
| Net Income | -5.02 | -5.02 | -6.06 | -6.73 | -5.46 | -1.71 | -0.65 | -0.71 |
| EPS (Recurring) | -8.67 | -12.64 | -40.62 | -80.50 | -128.35 | -37.56 | -14.31 | -15.62 |
| EPS (Basic, Before Extraordinaries) | -16.91 | -12.64 | -40.62 | -83.90 | -128.35 | -37.56 | -14.31 | -15.62 |
| EPS (Diluted) | -16.91 | -12.64 | -40.62 | -83.90 | -128.35 | -37.56 | -14.31 | -15.62 |
| EBITDA | -5.96 | -5.96 | -5.82 | -6.00 | -5.73 | -1.73 | -0.64 | -0.65 |
| Non-Operating Income (Expense) | 0.53 | 0.53 | 0.02 | -0.22 | 0.29 | -0.00 | 0.00 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.10 | 0.10 | 0.27 | 1.01 | 0.02 | 0.29 | - | - |
| Price To Sales Ratio | 256.32 | 175.94 | 671.71 | 9.20 | 863.45 | - | - | - |
| Gross Margin | -3,472.01 | -3,472.01 | -6,262.11 | 32.34 | -15.94 | - | -7.62 | 45.81 |
| Operating Margin | -51,515.17 | -51,515.17 | -97,344.76 | -3,903.69 | -66,963.68 | - | -520.54 | -652.05 |
| Net Margin | -40,439.10 | -40,439.10 | -95,739.17 | -4,304.81 | -63,748.32 | - | -525.75 | -711.32 |
| Shares Outstanding | 0.58 | 0.58 | 0.17 | 0.10 | 0.06 | 0.05 | 0.05 | 0.05 |
| Market Capitalization | 0.84 | 0.84 | 123.75 | 32.47 | 2,027.58 | 1,994.92 | - | - |
Income statement, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 | 2023S1 | 2022S2 | 2022S1 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.01 | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 | 0.00 | 0.01 |
| Cost of Goods Sold Incl. D&A | 0.23 | 0.22 | 0.23 | 0.17 | 0.13 | 0.07 | 0.00 | 0.01 |
| Gross Profit | -0.22 | -0.22 | -0.23 | -0.16 | -0.05 | 0.01 | -0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 3.60 | 2.37 | 3.05 | 2.71 | 3.35 | 2.72 | 4.29 | 1.44 |
| Research and Development | 2.36 | 1.38 | 1.05 | 0.73 | 1.15 | 0.41 | 0.30 | 0.10 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.81 | -2.59 | -3.28 | -2.88 | -3.40 | -2.71 | -4.29 | -1.44 |
| Interest Expense | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.40 | -0.01 | 0.00 | 0.00 |
| Net Income Before Taxes | -3.32 | -2.62 | -3.31 | -2.89 | -3.82 | -2.91 | -4.00 | -1.45 |
| Income Taxes | -0.63 | -0.27 | 0.00 | -0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -2.69 | -2.34 | -3.31 | -2.76 | -3.82 | -2.91 | -4.00 | -1.45 |
| Net Income From Continuing Operations | -2.68 | -2.34 | -3.30 | -2.76 | -3.82 | -2.91 | -4.01 | -1.44 |
| Net Income | -2.68 | -2.34 | -3.30 | -2.76 | -3.82 | -2.91 | -4.01 | -1.44 |
| EPS (Recurring) | -4.64 | -12.28 | -19.03 | -22.20 | -34.40 | -41.10 | -64.54 | -30.94 |
| EPS (Basic, Before Extraordinaries) | -4.64 | -12.28 | -19.03 | -22.20 | -37.14 | -40.98 | -64.55 | -30.95 |
| EPS (Diluted) | -4.64 | -12.28 | -19.03 | -22.20 | -37.14 | -40.98 | -64.55 | -30.95 |
| EBITDA | -3.59 | -2.37 | -3.10 | -2.72 | -3.31 | -2.69 | -4.29 | -1.44 |
| Non-Operating Income (Expense) | 0.53 | -0.00 | 0.01 | 0.01 | -0.01 | -0.21 | 0.29 | -0.00 |
| Stock Option Compensation Expense | 0.06 | 0.04 | 0.24 | 0.03 | 0.78 | 0.23 | - | 0.25 |
| Price To Sales Ratio | 256.32 | 969.99 | 781.84 | 70.94 | 11.80 | 72.76 | 1,262.87 | 6,378.09 |
| Gross Margin | -1,996.43 | -13,396.39 | -16,820.68 | -3,324.55 | -56.69 | 13.75 | -52.95 | 2.05 |
| Operating Margin | -35,268.19 | -160,788.25 | -238,316.84 | -58,124.19 | -4,254.18 | -3,537.55 | -153,237.59 | -25,010.00 |
| Net Margin | -24,826.44 | -145,445.96 | -239,827.29 | -55,651.67 | -4,784.70 | -3,803.47 | -143,301.79 | -25,062.69 |
| Shares Outstanding | 0.58 | 0.26 | 0.17 | 0.10 | 0.10 | 0.07 | 0.06 | 0.05 |
| Market Capitalization | 0.84 | 66.01 | 123.75 | 210.59 | 32.47 | 1,263.20 | 2,027.58 | 8,957.10 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 6.44 | 4.23 | 3.59 | 9.35 | 0.02 | 0.02 | 0.02 |
| Short Term Receivables | 0.03 | 0.03 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.09 | 0.06 | 0.00 | 0.02 | 0.02 | 0.00 |
| Other Current Assets | 0.36 | 0.54 | 0.51 | 0.28 | 0.01 | - | 0.00 |
| Total Current Assets | 6.83 | 4.89 | 4.38 | 9.63 | 0.05 | 0.04 | 0.02 |
| Net Property, Plant & Equipment | 1.50 | 1.53 | 1.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Note Receivable | - | - | - | - | 0.00 | 0.05 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 8.32 | 6.43 | 5.48 | 9.81 | 0.05 | 0.09 | 0.02 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.11 | 0.09 | 0.05 | 0.15 | 0.00 | 0.18 | 0.76 |
| Accounts Payable | 0.05 | 0.06 | 0.05 | 0.16 | 0.85 | 0.22 | 0.21 |
| Other Current Liabilities | 0.52 | 0.53 | 0.08 | 0.60 | 0.40 | 0.47 | 0.27 |
| Total Current Liabilities | 0.69 | 0.67 | 0.17 | 0.91 | 1.25 | 0.87 | 1.24 |
| Long Term Debt | 0.30 | 0.29 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.99 | 0.96 | 0.35 | 0.91 | 1.25 | 0.87 | 1.24 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 7.58 | 5.70 | 5.37 | 9.13 | -0.97 | -0.60 | -1.06 |
| Total Shareholders Equity | 7.58 | 5.70 | 5.37 | 9.13 | -0.97 | -0.60 | -1.06 |
| Accumulated Minority Interest | -0.24 | -0.23 | -0.23 | -0.22 | -0.22 | -0.18 | -0.16 |
| Total Equity | 7.33 | 5.46 | 5.14 | 8.90 | -1.20 | -0.78 | -1.22 |
| Total Liabilities & Stockholders Equity | 8.32 | 6.43 | 5.48 | 9.81 | 0.05 | 0.09 | 0.02 |
| Book Value Per Share | 13.08 | 32.80 | 52.13 | 146.75 | -21.42 | -13.10 | -23.21 |
| Tangible Book Value Per Share | 13.08 | 32.80 | 52.13 | 143.89 | -21.42 | -13.10 | -23.21 |
| Full-Time Employees | 26 | 19 | 17 | 11 | 5 | 17 | 20 |
| Price to Book Ratio | 0.05 | 8.49 | 5.13 | 29.62 | 45.41 | - | - |
| Return on Assets | -68.11 | -101.78 | -88.04 | -110.69 | -2,392.91 | -1,115.40 | - |
| Return on Equity | -75.70 | -109.58 | -92.92 | -133.90 | - | - | - |
| Return on Invested Capital | -63.74 | -101.23 | -121.48 | -59.80 | - | - | - |
| Quick Ratio | 9.97 | 7.13 | 25.58 | 10.61 | 0.02 | 0.02 | 0.02 |
| Current Ratio | 9.97 | 7.27 | 25.94 | 10.61 | 0.04 | 0.05 | 0.02 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY |
|---|---|---|---|---|---|---|---|---|
| Net Income | -5.03 | -5.03 | -6.07 | -6.74 | -5.46 | -1.75 | -0.67 | -0.74 |
| Depreciation | 0.44 | 0.44 | 0.34 | 0.10 | - | - | - | - |
| Other Funds (Non Cash) | -0.29 | -0.29 | 0.53 | 1.51 | 1.49 | 0.30 | 0.02 | 0.09 |
| Funds from Operations | -4.88 | -4.88 | -5.19 | -5.13 | -3.96 | -1.45 | -0.65 | -0.65 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.26 | 0.26 | 0.59 | -1.12 | -0.22 | 0.64 | 0.06 | -0.10 |
| Cash from Operating Activities | -4.62 | -4.62 | -4.60 | -6.25 | -4.18 | -0.81 | -0.59 | -0.74 |
| Capital Expenditures | -0.26 | -0.26 | -0.60 | -1.16 | -0.18 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.26 | -0.26 | -0.60 | -1.16 | -0.18 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 7.20 | 7.20 | 5.91 | 1.87 | 13.65 | 0.52 | 0.40 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 7.20 | 7.20 | 5.91 | 1.87 | 13.65 | 0.52 | 0.40 | 0.00 |
| Proceedsfrom Stock Options | 7.20 | 7.20 | 5.13 | 0.00 | 13.65 | 0.52 | 0.40 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.00 | -0.00 | 0.03 | -0.15 | 0.15 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | -0.02 | -0.11 | 0.29 | 0.18 | 0.70 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | -0.02 | -0.11 | - | - | - |
| Cash from Financing Activities | 7.08 | 7.08 | 5.84 | 1.65 | 13.69 | 0.81 | 0.59 | 0.70 |
| Net Change in Cash | 2.21 | 2.21 | 0.64 | -5.76 | 9.33 | 0.00 | -0.00 | -0.04 |
| Free Cash Flow | -4.87 | -4.87 | -5.20 | -7.20 | -4.18 | -0.81 | -0.59 | -0.74 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 | 2023S1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 6.44 | 3.35 | 4.23 | 7.29 | 3.59 | 5.11 |
| Short Term Receivables | 0.03 | 0.18 | 0.03 | 0.03 | 0.22 | 0.18 |
| Inventories | 0.00 | 0.05 | 0.09 | 0.13 | 0.06 | 0.02 |
| Other Current Assets | 0.36 | 0.57 | 0.54 | 0.60 | 0.51 | 0.66 |
| Total Current Assets | 6.83 | 4.15 | 4.89 | 8.03 | 4.38 | 5.97 |
| Net Property, Plant & Equipment | 1.50 | 1.57 | 1.53 | 1.41 | 1.10 | 0.68 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.37 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 8.32 | 5.72 | 6.43 | 9.44 | 5.48 | 7.03 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.11 | 0.26 | 0.09 | 0.27 | 0.05 | 0.05 |
| Accounts Payable | 0.05 | 0.04 | 0.06 | 0.12 | 0.05 | 0.41 |
| Other Current Liabilities | 0.52 | 0.06 | 0.53 | 0.30 | 0.08 | 0.33 |
| Total Current Liabilities | 0.69 | 0.37 | 0.67 | 0.69 | 0.17 | 0.79 |
| Long Term Debt | 0.30 | 0.28 | 0.29 | 0.33 | 0.18 | 0.13 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.99 | 0.64 | 0.96 | 1.03 | 0.35 | 0.92 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 7.58 | 5.31 | 5.70 | 8.64 | 5.37 | 6.33 |
| Total Shareholders Equity | 7.58 | 5.31 | 5.70 | 8.64 | 5.37 | 6.33 |
| Accumulated Minority Interest | -0.24 | -0.24 | -0.23 | -0.23 | -0.23 | -0.23 |
| Total Equity | 7.33 | 5.07 | 5.46 | 8.42 | 5.14 | 6.11 |
| Total Liabilities & Stockholders Equity | 8.32 | 5.72 | 6.43 | 9.44 | 5.48 | 7.03 |
| Book Value Per Share | 13.08 | 20.30 | 32.80 | 83.97 | 52.13 | 87.40 |
| Tangible Book Value Per Share | 13.08 | 20.30 | 32.80 | 83.97 | 52.13 | 82.23 |
| Price to Book Ratio | 0.05 | 11.59 | 8.49 | 23.26 | 5.13 | 13.84 |
| Return on Assets | -68.11 | -74.46 | -101.78 | -79.92 | -88.04 | -112.36 |
| Return on Equity | -75.70 | -80.87 | -109.58 | -87.87 | -92.92 | -129.10 |
| Return on Invested Capital | -34.06 | -41.85 | -55.19 | -30.71 | -68.98 | -45.00 |
| Quick Ratio | 9.97 | 11.21 | 7.13 | 11.40 | 25.58 | 7.56 |
| Current Ratio | 9.97 | 11.35 | 7.27 | 11.58 | 25.94 | 7.59 |
Cash flow, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 | 2023S1 |
|---|---|---|---|---|---|---|
| Net Income | -2.69 | -2.34 | -3.31 | -2.76 | -3.82 | -2.91 |
| Depreciation | 0.22 | 0.22 | 0.19 | 0.16 | 0.09 | 0.02 |
| Other Funds (Non Cash) | -0.11 | -0.17 | 0.42 | 0.11 | 1.48 | 0.02 |
| Funds from Operations | -2.58 | -2.30 | -2.70 | -2.49 | -2.26 | -2.87 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.89 | -0.62 | 0.25 | 0.35 | -0.53 | -0.59 |
| Cash from Operating Activities | -1.69 | -2.92 | -2.45 | -2.14 | -2.79 | -3.46 |
| Capital Expenditures | -0.11 | -0.14 | -0.36 | -0.25 | -0.46 | -0.71 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.11 | -0.14 | -0.36 | -0.25 | -0.46 | -0.71 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 5.13 | 2.07 | 0.00 | 5.91 | 1.87 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 5.13 | 2.07 | 0.00 | 5.91 | 1.87 | 0.00 |
| Proceedsfrom Stock Options | 5.13 | 2.07 | -0.00 | 5.13 | -0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.17 | 0.16 | -0.19 | 0.22 | -0.00 | -0.15 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -0.09 | 0.07 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 |
| Cash from Financing Activities | 4.90 | 2.18 | -0.25 | 6.09 | 1.73 | -0.08 |
| Net Change in Cash | 3.09 | -0.88 | -3.06 | 3.70 | -1.52 | -4.24 |
| Free Cash Flow | -1.81 | -3.06 | -2.81 | -2.39 | -3.25 | -3.95 |
Revenue breakdown
| Total In Vitro & In Vivo Diagnostic Substances revenue | 2024: 6.33K 2025: 12.42K |
|---|---|
| United Kingdom | 2024: 6.33K 2025: 12.42K |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.50% | 0.0M | 1.3M | 386.38K |
| 2026-10-15 | 0.67% | 0.0M | 1.3M | 596.80K |
| 2026-09-30 | 0.50% | 0.0M | 1.3M | 1.75M |
| 2026-09-15 | 2.28% | 0.0M | 1.3M | 1.79M |
| 2026-08-31 | 2.53% | 0.0M | 0.8M | 1.80M |
| 2026-08-14 | 2.96% | 0.0M | 0.8M | 2.16M |
| 2026-07-31 | 3.99% | 0.0M | 0.8M | 2.19M |
| 2026-07-15 | 3.17% | 0.0M | 0.8M | 2.02M |
| 2026-06-30 | 7.77% | 0.1M | 0.8M | 1.25M |
| 2026-06-15 | 5.24% | 0.0M | 0.8M | 1.21M |
| 2026-05-29 | 5.46% | 0.0M | 0.8M | 1.19M |
| 2026-05-15 | 2.00% | 0.0M | 0.8M | 547.99K |
| 2026-04-30 | 0.76% | 0.0M | 0.8M | 515.71K |
| 2026-04-15 | 70.82% | 0.2M | 0.3M | 506.20K |
| 2026-03-31 | 0.00% | 0.0M | 0.3M | 165.55K |
| 2026-03-13 | 0.15% | 0.0M | 0.3M | 12.02K |
| 2026-02-27 | 0.80% | 0.0M | 0.3M | 208.71K |
| 2026-02-13 | 0.30% | 0.0M | 0.3M | 207.73K |
| 2026-01-30 | 0.98% | 0.0M | 0.3M | 207.73K |
| 2026-01-15 | 0.88% | 0.0M | 0.3M | 204.89K |
Option chain
expiry 2026-11-12| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-10-29 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-29 | SEC |
| 2026-10-21 | 3 | Initial statement of beneficial ownership of securities | 2026-10-05 | SEC |
| 2026-10-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-09 | SEC |
| 2026-09-10 | 424B3 | SEC | ||
| 2026-09-04 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-04 | SEC |
| 2026-09-04 | 424B5 | SEC | ||
| 2026-09-03 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-09-02 | F-3/A | SEC | ||
| 2026-08-26 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-21 | SEC |
| 2026-08-18 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-18 | SEC |
| 2026-07-31 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-31 | SEC |
| 2026-07-24 | F-3 | Registration statement for specified transactions by certain foreign private issuers | SEC | |
| 2026-07-16 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-16 | SEC |
| 2026-07-10 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-10 | SEC |
| 2026-07-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-09 | SEC |
| 2026-07-06 | 20-F | Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer. | 2026-03-31 | SEC |
| 2026-06-24 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-24 | SEC |
| 2026-06-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-12 | SEC |
| 2026-05-26 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-26 | SEC |
| 2026-05-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-22 | SEC |
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-04-14 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-14 | SEC |
| 2026-04-10 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-10 | SEC |
| 2026-03-31 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-18 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-03-18 | SEC |
| 2026-03-18 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-18 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-18 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-18 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| JANE STREET GROUP, LLC | 0.13% |
| UBS Group AG | 0.02% |
| Caitong International Asset Management Co., Ltd | 0.00% |
Funds
| Fund | % owned |
|---|---|
| - | |
OakChart. VRAX. Cached 15 minutes.
Some panels did not load: insider.